Summary & Overview
HCPCS J9036: Bendamustine Hydrochloride Injection, 1 mg
HCPCS Level II code J9036 identifies the injectable chemotherapy agent bendamustine hydrochloride (belrapzo/bendamustine), billed per 1 mg. As a chemotherapeutic drug code, it is central to billing for oncology infusion services across hospital outpatient departments, physician offices, and ambulatory infusion centers. Nationally, accurate use of J9036 matters for clinical documentation, drug-utilization tracking, and reimbursement for cancer care delivery.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how J9036 is used in practice, benchmarks and reimbursement context where available, and the clinical setting in which administrations commonly occur. The publication addresses billing considerations tied to unit-based reporting for a high-cost oncologic drug and explains the typical sites of service for administration.
This summary is designed for billing managers, oncology clinicians, revenue cycle staff, and policy analysts seeking a national-level reference for J9036. Data not available in the input is noted where applicable; the report focuses on code definition, service context, payer scope, and practical billing implications for systemic chemotherapy administrations.
Billing Code Overview
HCPCS Level II code J9036 represents the injection of bendamustine hydrochloride, specifically belrapzo/bendamustine, billed per 1 mg unit. This code describes a systemic antineoplastic (chemotherapy) injectable medication used in oncology treatment regimens.
-
Service type: Drug administration (intravenous infusion or injection) of bendamustine hydrochloride
-
Typical site of service: Hospital outpatient infusion centers, physician offices, and ambulatory infusion clinics
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old person with relapsed follicular lymphoma or chronic lymphocytic leukemia receiving intravenous bendamustine hydrochloride as part of an outpatient oncology infusion. The patient presents to an outpatient infusion center or hospital outpatient department after evaluation by a hematology–oncology physician. Baseline labs (CBC with differential, comprehensive metabolic panel, and hepatitis B screen) are reviewed and documented prior to therapy. Vascular access is obtained (peripheral IV or implanted port). The pharmacy prepares the weight‑based dose converted to milligrams; billing for the drug uses J9036 per milligram. During infusion the nurse performs routine chemotherapy safety checks, monitors vital signs, and documents infusion start/stop times and any immediate adverse reactions. Post‑infusion monitoring includes assessment for infusion‑related reactions, hematologic toxicity education, and scheduling of follow‑up labs and next treatment cycle. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and physician offices with oncology infusion capability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When part of the prepared bendamustine dose is discarded after removal from vial and documentation supports waste. |